Loading
companiesCompany
3SBio
3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.
Also called: Shenyang Sunshine PharmaceuticalSansheng Pharmaceutical
Overview
3SBio, listed in Hong Kong, is one of China's largest biologics makers, with a long-standing business in recombinant proteins (erythropoietin, thrombopoietin). In oncology its Fc-engineered HER2 antibody inetetamab (Cipterbin) was approved by the NMPA in June 2020 with vinorelbine for HER2-positive metastatic breast cancer. A 2025 licence of its PD-1 and VEGF bispecific antibody to Pfizer brought the company global attention.
Headquarters
Shenyang, China, CN
Scorecard
All companies#194of 1244 companies, score 29
- approved products +6
- phase 1/2 +3
- targets +6
- modalities +4
- regions +1
- registry trials +9
1 approved, 0 in phase 3, 3 earlier, 3 targets, 20 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedAnti-HER2 monoclonal antibody, Fc-engineered
Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer.
Phase 2monoclonal antibody
SSGJ-612 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at HER2.
Phase 2monoclonal antibody
SSGJ-705 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at PD-1 and HER2.
Phase 2bispecific antibody
SSGJ-706 is an experimental bispecific antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and PD-L1.
Similar pages
- CompanyWuXi Biologics
Shares Monoclonal antibodies and the tag china.
- TreatmentSugemalimab
Shares Monoclonal antibodies and the tag china.
- TreatmentEnvafolimab
Shares Monoclonal antibodies and the tag china.
- TreatmentAdebrelimab
Shares Monoclonal antibodies and the tag china.
- TreatmentSintilimab
Shares Monoclonal antibodies and the tag china.
- CompanyJiangsu Hengrui Pharmaceuticals
Shares HER2-positive breast cancer and the tag china.
- TrialRC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
Shares Inetetamab, HER2-positive breast cancer.
cancers
technologies
drugs
ApprovedAnti-HER2 monoclonal antibody, Fc-engineered
Phase 2monoclonal antibody
Phase 2monoclonal antibody
Phase 2bispecific antibody
trials
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal CancersA Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） PatientsPhase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer PainSSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid TumorsSSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid TumorsSSGJ-707 in Advanced Non-Small Cell Lung Cancer